Trials / Completed
CompletedNCT00210379
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG) · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab | |
| DRUG | CHOP | |
| DRUG | intrathecal methotrexate | |
| PROCEDURE | radiotherapy |
Timeline
- Start date
- 2000-11-01
- Primary completion
- 2004-11-01
- Completion
- 2007-03-01
- First posted
- 2005-09-21
- Last updated
- 2009-07-22
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00210379. Inclusion in this directory is not an endorsement.